Catalyst Wire Dossier Catalyst Wire Dossier

CB-NK cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CB-NK cells, covering 2026-01-26 to 2026-01-26. Get the full timeline:

Most recent: Clinical Trial Update: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) [Phase 1]

See pricing